Analysis of biomarkers after intramuscular injection of Vaxfectin®-formulated hCMV gB plasmid DNA

Vaccine

Volumn 27, Issue 52, 2009, Pages 7409-7417

  Vilalta, Adrián ^a   Shlapobersky, Mark ^a   Wei, Qun ^a   Planchon, Rodrick ^a   Rolland, Alain ^a   Sullivan, Sean ^a  

^a VICAL INC   (United States)

Author keywords

Biomarker; Cationic lipid adjuvant; CMV; pDNA vaccine

Indexed keywords

BIOLOGICAL MARKER; LIPID; PLASMID DNA; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG; VAXFECTIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOMETRY; DNA IMMUNIZATION; DNA MICROARRAY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG MECHANISM; FEMALE; GENE CONTROL; GENE EXPRESSION; HUMAN CYTOMEGALOVIRUS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; CYTOMEGALOVIRUS VACCINES; FEMALE; GENE EXPRESSION PROFILING; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED BALB C; MUSCLE, SKELETAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHOSPHATIDYLETHANOLAMINES; PLASMIDS; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 70649091130     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.08.075     Document Type: Article

References (41)

1. Regnstrom K., Ragnarsson E.G., Rydell N., Sjoholm I., and Artursson P. Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo. Pharmacogenomics J 2 1 (2002) 57-64
2. Regnstrom K., Ragnarsson E., and Artursson P. Gene expression after vaccination of mice with formulations of diphtheria toxoid or tetanus toxoid and different adjuvants: identification of shared and vaccine-specific genes in spleen lymphocytes. Vaccine 21 19-20 (2003) 2307-2317
3. Regnstrom K., and Burgess D.J. Pharmacogenomics and its potential impact on drug and formulation development. Crit Rev Ther Drug Carrier Syst 22 5 (2005) 465-492
4. Halonen S.K., Woods T., McInnerney K., and Weiss L.M. Microarray analysis of IFN-gamma response genes in astrocytes. J Neuroimmunol 175 1-2 (2006) 19-30
5. Purcell M.K., Nichols K.M., Winton J.R., Kurath G., Thorgaard G.H., Wheeler P., et al. Comprehensive gene expression profiling following DNA vaccination of rainbow trout against infectious hematopoietic necrosis virus. Mol Immunol 43 13 (2006) 2089-2106
6. Regnstrom K., Ragnarsson E.G., Fryknas M., Koping-Hoggard M., and Artursson P. Gene expression profiles in mouse lung tissue after administration of two cationic polymers used for nonviral gene delivery. Pharm Res 23 3 (2006) 475-482
7. Rogers J.V., Casbohm S.L., Giannunzio L.F., Sinnott L.T., Rust S.W., Brys A.M., et al. Transcriptional analysis of protective antigen-stimulated PBMC from non-human primates vaccinated with the anthrax vaccine absorbed. Vaccine 24 17 (2006) 3609-3617
8. Royaee A.R., Jong L., Mendis C., Das R., Jett M., and Yang D.C. Cholera toxin induced novel genes in human lymphocytes and monocytes. Mol Immunol 43 8 (2006) 1267-1274
9. Mosca F., Tritto E., Muzzi A., Monaci E., Bagnoli F., Iavarone C., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci USA 105 30 (2008) 10501-10506
10. Byon J.Y., Ohira T., Hirono I., and Aoki T. Comparative immune responses in Japanese flounder, Paralichthys olivaceus after vaccination with viral hemorrhagic septicemia virus (VHSV) recombinant glycoprotein and DNA vaccine using a microarray analysis. Vaccine 24 7 (2006) 921-930
11. Hartikka J., Bozoukova V., Ferrari M., Sukhu L., Enas J., Sawdey M., et al. Vaxfectin enhances the humoral immune response to plasmid DNA-encoded antigens. Vaccine 19 15-16 (2001) 1911-1923
12. Reyes L., Hartikka J., Bozoukova V., Sukhu L., Nishioka W., Singh G., et al. Vaxfectin enhances antigen specific antibody titers and maintains Th1 type immune responses to plasmid DNA immunization. Vaccine 19 27 (2001) 3778-3786
13. Fischer L., Minke J., Dufay N., Baudu P., and Audonnet J.C. Rabies DNA vaccine in the horse: strategies to improve serological responses. Vaccine 21 31 (2003) 4593-4596
14. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 101 37 (2004) 13601-13606
15. Sedegah M., Rogers W.O., Belmonte A., Belmonte M., Banania G., Patterson N., et al. Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines. Vaccine 24 11 (2006) 1921-1927
16. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., et al. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum Vaccines 3 5 (2007) 157-164
17. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., et al. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J Infect Dis 197 12 (2008) 1643-1652
18. ®-formulated measles DNA vaccine encoding the hemagglutinin and fusion proteins protects juvenile and infant rhesus macaques from measles. Clin Vaccine Immunol 15 8 (2008) 1214-1221
19. Selinsky C., Luke C., Wloch M., Geall A., Hermanson G., Kaslow D., et al. A DNA-based vaccine for the prevention of human cytomegalovirus-associated diseases. Hum Vaccines 1 1 (2005) 16-23
20. Dennis Jr. G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., et al. DAVID: database for annotation, visualization, and integrated discovery. Genome Biol 4 5 (2003) P3
21. ® Reverse Transcription Polymerase Chain Reaction (RT-PCR) in vitro potency assay for plasmid-based vaccine products. Mol Biotechnol (2008)
22. Margalith M., and Vilalta A. Sustained protective rabies neutralizing antibody titers after administration of cationic lipid-formulated pDNA vaccine. Genet Vaccines Ther 4 (2006) 2
23. Rosenkrands I., Agger E.M., Olsen A.W., Korsholm K.S., Andersen C.S., Jensen K.T., et al. Cationic liposomes containing mycobacterial lipids: a new powerful Th1 adjuvant system. Infect Immun 73 9 (2005) 5817-5826
24. Yan W., Chen W., and Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol Immunol 44 15 (2007) 3672-3681
25. Bergmann-Leitner E.S., and Leitner W.W. Danger, death and DNA vaccines. Microbes Infect 6 3 (2004) 319-327
26. Albert M.L., Sauter B., and Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392 6671 (1998) 86-89
27. Li A.F., Hough J., Henderson D., and Escher A. Co-delivery of pro-apoptotic BAX with a DNA vaccine recruits dendritic cells and promotes efficacy of autoimmune diabetes prevention in mice. Vaccine 22 13-14 (2004) 1751-1763
28. Chattergoon M.A., Muthumani K., Tamura Y., Ramanathan M., Shames J.P., Saulino V., et al. DR5 activation of caspase-8 induces DC maturation and immune enhancement in vivo. Mol Ther 16 2 (2008) 419-426
29. Dupuis M., Denis-Mize K., LaBarbara A., Peters W., Charo I.F., McDonald D.M., et al. Immunization with the adjuvant MF59 induces macrophage trafficking and apoptosis. Eur J Immunol 31 10 (2001) 2910-2918
30. Sieling P.A., Chung W., Duong B.T., Godowski P.J., and Modlin R.L. Toll-like receptor 2 ligands as adjuvants for human Th1 responses. J Immunol 170 1 (2003) 194-200
31. Schellack C., Prinz K., Egyed A., Fritz J.H., Wittmann B., Ginzler M., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 24 26 (2006) 5461-5472
32. Seya T., Akazawa T., Tsujita T., and Matsumoto M. Role of Toll-like receptors in adjuvant-augmented immune therapies. Evid Based Complement Altern Med 3 1 (2006) 31-38 [discussion 133-7]
33. Johnston D., Zaidi B., and Bystryn J.C. TLR7 imidazoquinoline ligand 3M-019 is a potent adjuvant for pure protein prototype vaccines. Cancer Immunol Immunother 56 8 (2007) 1133-1141
34. Plavec I., Sirenko O., Privat S., Wang Y., Dajee M., Melrose J., et al. Method for analyzing signaling networks in complex cellular systems. Proc Natl Acad Sci USA 101 5 (2004) 1223-1228
35. Oda K., and Kitano H. A comprehensive map of the toll-like receptor signaling network. Mol Syst Biol 2 (2006) 0015
36. Takeshita F., Tanaka T., Matsuda T., Tozuka M., Kobiyama K., Saha S., et al. Toll-like receptor adaptor molecules enhance DNA-raised adaptive immune responses against influenza and tumors through activation of innate immunity. J Virol 80 13 (2006) 6218-6224
37. Wiendl H., Hohlfeld R., and Kieseier B.C. Immunobiology of muscle: advances in understanding an immunological microenvironment. Trends Immunol 26 7 (2005) 373-380
38. Wiendl H., Hohlfeld R., and Kieseier B.C. Muscle-derived positive and negative regulators of the immune response. Curr Opin Rheumatol 17 6 (2005) 714-719
39. Nukuzuma C., Ajiro N., Wheeler C.J., and Konishi E. Enhancing effect of Vaxfectin on the ability of a Japanese encephalitis DNA vaccine to induce neutralizing antibody in mice. Viral Immunol 16 2 (2003) 183-189
40. Van Snick J., Cayphas S., Szikora J.P., Renauld J.C., Van Roost E., Boon T., et al. cDNA cloning of murine interleukin-HP1: homology with human interleukin 6. Eur J Immunol 18 2 (1988) 193-197
41. Matsuda T., Yamasaki K., Taga T., Hirano T., and Kishimoto T. Current concepts of B cell modulation. Int Rev Immunol 5 2 (1989) 97-109